China: Anti-Diabetic Drug Market Report 2008

Table of Contents

METHODOLOGY FOR THE ANNUAL CHINA DRUG MARKET REPORTS

CHAPTER I - SUMMARY OF THE ANTI-DIABETIC DRUG MARKET

• Section I: Overview of Diabetes in China
  • 1.1 Diabetes and Its Classification
  • 1.2 Diabetes Symptoms and Characteristics
  • 1.3 Complications of Diabetes
  • 1.4 Diabetes in China
• Section 2: Summary of Anti-diabetic Drugs and their Classifications
  • 2.1 Key Oral Anti-diabetic Drugs (Western Medicine)
  • 2.2 TCM Blood-sugar Lowering Drugs
  • 2.3 Insulin and Related Drugs

CHAPTER II - SUMMARY OF THE GLOBAL ANTI-DIABETIC DRUG MARKET

• Section 1: New Approvals of Anti-diabetic Drugs in 2007
• Section 2: Summary of Global Anti-diabetic Drug Market
  • 2.1 Global Market Sizes and Growth Rates of Anti-diabetic Drugs (2004-2007)
  • 2.2 Anti-diabetic Drugs as the Top 5th Best Selling Category in 2007
  • 2.3 Anti-diabetic Drugs Listed among the Top 50 Best Selling Drugs in 2006
  • 2.4 Global Market Shares of Oral Anti-diabetic Drugs vs. Insulin and Insulin Analogs (2003-2007)

CHAPTER III - ANALYSIS OF THE CHINESE ANTI-DIABETIC DRUG MARKET

• Section 1: Sizes and Annual Growth Rates of the Chinese Anti-diabetic Drug Market (2002-2007)
  • 1.1 Market Shares of Anti-diabetic Drugs by Category in China 2007
  • 1.2 Market Sizes of Key Anti-diabetic Drugs by Category in China 2007
  • 1.3 Sales and Manufacturers of the Top 10 Best Selling Oral Anti-diabetic Drugs in China 2007
  • 1.4 Growth Forecast of China' s Anti-diabetic Drug Market by 2012
• Section 2: Hospital Market Shares of Anti-diabetic Drug Manufacturers
  • 2.1 Market Shares of the Top 20 Pharmaceutical Companies in the Chinese Anti-diabetic Drug Market (2005-2007)
  • 2.2 Sales of the Top 20 Pharmaceutical Companies in the Chinese Anti-diabetic Drug Market (2005-2007)
  • 2.3 Analysis of Market Concentration of the Top 4 and Top 8 Pharmaceutical Companies by Herfindahl-Hirschman Index
• Section 3: Analysis of Hospital Market Shares and Annual Growth Rates of the Top 10 Best Selling Anti-diabetic Drugs in China (2005-2007)

CHAPTER IV MARKET SHARE ANALYSIS OF THE TOP 10 KEY ANTI-DIABETIC DRUGS & COMPETITORS IN CHINA

• Section 1: Manufacturers, Market Sizes and Shares for Insulin
• Section 2: Manufacturers, Market Sizes and Shares for Acarbose
• Section 3:Manufacturers, Market Sizes and Shares for Metformin
• Section 4:Manufacturers, Market Sizes and Shares for Repaglinide
• Section 5:Manufacturers, Market Sizes and Shares for Rosiglitazone
• Section 6:Manufacturers, Market Sizes and Shares for Glipizide
• Section 7: Manufacturers, Market Sizes and Shares for Gliquidone
• Section 8:Manufacturers, Market Sizes and Shares for Gliclazide
• Section 9:Manufacturers, Market Sizes and Shares for Nateglinide
• Section 10:Manufacturers, Market Sizes and Shares for Xiaoke Wan (Formulated)

CHAPTER V - LIST OF BRAND NAMES, GENERIC NAMES, PRICES AND MANUFACTURERS OF ANTI-DIABETIC DRUGS IN CHINA ANTI-DIABETIC DRUGS ON THE NATIONAL HEALTHCARE INSURANCE COVERAGE LIST

• Section 1: Package, Unit, Retail Price of anti-diabetic Drugs and their Manufacturers in China
• Section 2: Anti-diabetic Drugs on the National Healthcare Insurance and Work Injury Insurance List
  • 2.1 Types of Insurance, Formula and Reimbursement Restriction

CHAPTER VI R& D OF ANTI-DIABETIC DRUGS

• Section 1: Non-insulin Treatments for Type II Diabetes
  • 1.1 Oral Anti-diabetic Drug as First Line Treatment
  • 1.2 New Treatment Options: Incretin Treatment
  • 1.3 Other Anti-diabetic Drugs under Phase II/III Clinical Studies
  • 1.4 The US Market of Anti-diabetic Drugs
• Section 2: Anti-diabetic Drugs Recently Approved or Currently under Clinical Study
  • 2.1 Denmark' s Novo Nordisk Filed Regulatory Approval of its Type 2 Diabetes Drug Liraglutide in the US and Europe Simultaneously
  • 2.2 New Anti-diabetic Drug Development by Eli Lilly and Transition
  • 2.3 FDA Approved Novo Nordisk' s NovoLog for Treating Pediatric Diabetes Patients
  • 2.4 FDA Accepted UCB' s NDA Application for Lacosamide for the Treatment of Adults with Diabetic Neuropathic Pain
  • 2.5 US FDA Approved Amylin' s SymlinPen 120 and SymlinPen 60 Pen-injector Devices

CHAPTER VII - GOVERNMENT POLICIES FOR THE CHINESE ANTI-DIABETIC DRUG MARKET

EXHIBITS

Table A Hospital Coverage for the Monitoring and Tracking of Drug Prescription and Purchasing Data in China.

TABLES

• Table 1: Complication in Chinese Diabetes Patients
• Table 2: DM and IGT Disease Rates (%) in Different BMI Populations
• Table 3: Newly Approved Anti-diabetic Drug (New Molecule Entity) in 2007
• Table 4: The Top 10 Best Selling Drug Categories in the World in 2007
• Table 5: Anti-diabetic Drugs on the List of the World Top 50 Best Selling Drugs in 2006
• Table 6: Sales of Anti-diabetic drugs by Categories in China 2007
• Table 7: Top 10 Best Sellers of Oral Anti-diabetic Drugs in China 2007
• Table 8: Market Shares of the Top 20 Pharmaceutical Companies in the Chinese Anti-diabetic Drug Hospital Market 2005-2007
• Table 9: Sales of Anti-diabetic drugs of the Top 20 Pharmaceutical Companies in the Chinese Hospital Marekt 2005-2007
• Table 10: Market Concentration Rates of the Chinese Anti-diabetic Drugs Hospital Market 2005 - 2007
• Table 11: Market Shares and Growth Rates of the Top 10 Anti-diabetic drugs in China (2005-2007)
• Table 12: Manufacturers, Market Sizes and Shares for Insulin (2006-2007)
• Table 13: Sales of Insulin from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007
• Table 14: Manufacturers, Market Sizes and Shares for Acarbose 2006-2007
• Table 15: Sales of Acarbose from Top Pharmaceutical Companies in the Chinese Hospital Market 2007
• Table 16: Manufacturers, Market Sizes and Shares for Metformin 2006-2007
• Table 17: Sales of Metformin from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007
• Table 18: Manufacturers, Market Sizes and Shares for Repaglinide 2006-2007
• Table 19: Sales of Repaglinide from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007
• Table 20: Manufacturers, Market Sizes and Shares for Rosiglitazone 2006-2007
• Table 21: Sales of Rosiglitazone from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007
• Table 22: Manufacturers, Market Sizes and Shares for Glipizide 2006-2007
• Table 23: Sales of Glipizide from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007
• Table 24: Manufacturers, Market Sizes and Shares for Gliquidone 2006-2007
• Table 25: Sales of Gliquidone from the Top Pharmaceutical Companies in the Chinese Hospital Market 2007
• Table 26: Manufacturers, Market Sizes and Shares for Gliclazide 2006-2007
• Table 27: Sales of Gliclazide from the Top Pharmaceutical Companies in the Chinese Hospital Market 2006-2007
• Table 28: Manufacturers, Market Sizes and Shares for Nateglinide 2006-2007
• Table 29: Brand Names, Packages and Retail Prices of Anti-Diabetic Drugs and Their Manufacturers in China 2007
• Table 30: Anti-diabetics of Western Medicine Covered by the National Basic Healthcare Insurance
• Table 31: Anti-diabetics of Traditional Chinese Medicine (TCM) Covered by the National Basic Healthcare Insurance
• Table 32: Anti-diabetic Drugs under Phase II/III Clinical Studies

FIGURES

• Figure 1: Anti-diabetic Drugs in China
• Figure 2: Global Market Sizes of Anti-diabetic Drugs (2004-2007)
• Figure 3: Global Market Size of Oral Anti-diabetic Drugs and Insulin/Insulin Analogs (2003 - 2007)
• Figure 4: Sizes and Growth Rates of the Chinese Anti-diabetic Drug Market (2002-2007)
• Figure 5: Market Shares of Different Anti-diabetic Drug Categories in China 2007
• Figure 6: Market Sizes and Growth Rates of Xiaoke Wan 2005-2007
• Figure 7: Sales vs. Prescription Volume of None-Insulin Anti-diabetic Drugs in United States (2006)